Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.65 |
| ▸ | CES1 | P23141 | 2/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.53 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.53 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 6/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394754 | 1.00 | CES2 (0.65) | CES2CES1CA1CA2MAPT | |
| SCHEMBL4394758 | 1.00 | CES2 (0.65) | CES2CES1CA1CA2MAPT | |
| SCHEMBL2019776 | 0.94 | CA1 (0.61) | CES2CES1CA1CA2MAPT | |
| SCHEMBL8937488 | 0.85 | ALDH1A1 (0.60) | CES2CES1CA1CA2MAPT | |
| SCHEMBL8937491 | 0.85 | ALDH1A1 (0.60) | CES2CES1CA1CA2MAPT | |
| SCHEMBL8937439 | 0.85 | GRM5 (0.49) | CES2CES1CA1CA2MAPT | |
| SCHEMBL8937271 | 0.85 | CES2 (0.47) | CES2CES1CA1CA2MAPT | |
| SCHEMBL8937278 | 0.85 | CES2 (0.47) | CES2CES1CA1CA2MAPT | |
| SCHEMBL8937436 | 0.85 | GRM5 (0.49) | CES2CES1CA1CA2MAPT | |
| SCHEMBL8937442 | 0.85 | GRM5 (0.49) | CES2CES1CA1CA2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626046-B1 | Photochromic oxazine compounds and methods for their manufacture | ESSILOR INT (FR) | 2014-11-19 | — | — | EP | disclosed |
| EP-1458695-B1 | Method for the manufacture of photochromic oxazine compounds and compounds obtainable therefrom | ESSILOR INT (FR) | 2012-10-03 | — | — | EP | disclosed |
| EP-1446390-B1 | PHOTOCHROMIC OXAZINE COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | ESSILOR INT (FR) | 2009-12-02 | — | — | EP | disclosed |
| EP-1626046-A1 | Photochromic oxazine compounds and methods for their manufacture | Johson & Johnson Vision Care Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-6720420-B2 | AROMATIC, HETEROAROMATIC, OR ALIPHATIC SUBSTITUENTS AT THE 2 POSITION OF THE OXAZINE MOIETY; REACTING 3,3-DISUBSTITUTED ACRYLIC ACID, AZIDE SOURCE, QUINONE WITH CATALYTIC TRIPHENYLARSENIC OXIDE AND DBU; QUICKLY FADING GRAY COLOR | JOHNSON & JOHNSON VISION CARE, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6686466-B2 | HEATING AN ISOCYANATE DERIVATIVE WITH A SYMMETRIC QUINONE IN PRESENCE OF TRIPHENYLARSEN OXIDE CATALYST TO FORM 2,2-DIPHENYL-PHENANTHRO (9,10)-2H-(1,4)-OXAZINE DERIVATIVES | JOHNSON & JOHNSON VISION CARE, INC. | 2004-02-03 | — | — | US | disclosed |
| US-20030149032-A1 | Photochromic oxazine compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2003-08-07 | — | — | US | disclosed |
| US-20030125552-A1 | Photochromic oxazine compounds and methods for their manufacture | ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE) (FR) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149032-A1 | Photochromic oxazine compounds and methods for their manufacture | PPOX, TYR, DHPS | CES2 1826/4885CES1 3890/4885CA1 3241/4885 |
| US-20030125552-A1 | Photochromic oxazine compounds and methods for their manufacture | PPOX, DHPS, ALDH1A2 | CES2 1101/4885CES1 4060/4885CA1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.